Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
-
- Ling Xu
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Amarendra Pegu
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Ercole Rao
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Nicole Doria-Rose
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Jochen Beninga
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Krisha McKee
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Dana M. Lord
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Ronnie R. Wei
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Gejing Deng
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Mark Louder
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Stephen D. Schmidt
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Zachary Mankoff
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Lan Wu
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Mangaiarkarasi Asokan
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Christian Beil
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Christian Lange
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Wulf Dirk Leuschner
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Jochen Kruip
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Rebecca Sendak
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- Young Do Kwon
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Tongqing Zhou
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Xuejun Chen
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Robert T. Bailer
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Keyun Wang
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Misook Choe
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Lawrence J. Tartaglia
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
-
- Dan H. Barouch
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
-
- Sijy O’Dell
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- John-Paul Todd
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Dennis R. Burton
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
-
- Mario Roederer
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Mark Connors
- National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Richard A. Koup
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Peter D. Kwong
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Zhi-yong Yang
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
-
- John R. Mascola
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
-
- Gary J. Nabel
- Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
Description
<jats:title>A triple threat for HIV</jats:title> <jats:p> The HIV virus continually evolves tricks to evade elimination by the host. Prevention and a cure will likely rely on broadly neutralizing antibodies that can recognize and conquer multiple viral strains or subtypes. Xu <jats:italic>et al.</jats:italic> engineered a single antibody molecule to recognize three highly conserved proteins needed for HIV infection (see the Perspective by Cohen and Corey). This “trispecific” antibody uses two sites (V1V2 and MPER) to bind HIV-infected cells, while the third site (CD4bs) recruits killer T lymphocytes that can eliminate the virus. When tested against >200 different HIV strains, trispecific antibodies were highly potent and broadly neutralized ∼99% of HIV viruses. This approach could potentially simplify HIV treatment regimens and improve therapy response. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6359" page="85" related-article-type="in-this-issue" vol="358" xlink:href="10.1126/science.aan8630">85</jats:related-article> ; see also p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6359" page="46" related-article-type="in-this-issue" vol="358" xlink:href="10.1126/science.aap8131">46</jats:related-article> </jats:p>
Journal
-
- Science
-
Science 358 (6359), 85-90, 2017-10-06
American Association for the Advancement of Science (AAAS)
- Tweet
Details 詳細情報について
-
- CRID
- 1360579816327647360
-
- ISSN
- 10959203
- 00368075
-
- Data Source
-
- Crossref